Professor of transplant inflammation and repair
Anthony Dorling qualified in medicine from the University of London in 1987, did general medical training in hospitals around the south east of England and gained membership of the Royal College of Physicians in 1990. After studying for a PhD at the Royal Postgraduate Medical School, he began specialist training in nephrology in 1995, alongside an appointment as lecturer in immunology and renal medicine. His training finished in 2001, when he was appointed senior lecturer in immunology at Imperial College and honorary consultant nephrologist at the Hammersmith Hospital in 2001, becoming a Reader in 2005. He was awarded fellowship of the Royal College of Physicians in the same year.
In October 2009, Anthony was appointed to a personal Chair in Transplant Inflammation and Repair at King's College London, based at Guy's Hospital, and he is an honorary consultant in nephrology. He has an active research group within the department of Inflammation Biology at King's College London, is chief investigator of the OuTSMART study, and chairs the Renal Project Board Steering Committee.
In the last five years, Anthony's clinical research focus has been the humoral, cellular and molecular mechanisms involved in transplant rejection. Clinically, he has been working in two main areas:
- antibody-incompatible transplants, attempting to understand 'accommodation' and developing new ways to overcome the problems associated with HLA antibodies
- chronic rejection – using an observational study and two randomised controlled clinical trials (RituxiCAN-C4 and OuTSMART).
Anthony's laboratory work is focused on the role clotting proteins play in inflammatory disease. He has shown that inhibiting coagulation protease activation within transplanted organs has a significant impact on rejection, mostly by preventing thrombin-mediated signalling through protease activated receptors, which is required to establish tissue chemokine gradients to initiate leukocyte recruitment into organs. In addition, the same mechanisms appear to have profound importance in directing the way that immune cells work, in both atherosclerosis and in the thickened vessels typically seen in patients with chronic rejecton.
Tel: 020 7188 5880
Secretary: Jenny Owen/Irene Miles
Secretary tel: 020 7188 5667
Email: [email protected]
- Optimising transplant survival
- Chronic rejection of kidney allografts
- Antibody-incompatible renal transplantation
Last updated: April 2022